Intelligent Investor

Burgundy Diamond Mines Limited (ASX: BDM) - Announcements

- Current share price for BDM : $0.160

ASX company news and announcements for Burgundy Diamond Mines Limited (BDM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Burgundy Diamond Mines Limited (BDM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Burgundy Diamond Mines Limited (BDM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Burgundy Diamond Mines Limited (BDM)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$227 Half Year Results 26 Feb 2010 2:54PM n/a $0.160 $0.170 n/a
$227 Half Yearly Report and Accounts 26 Feb 2010 2:07PM n/a $0.160 $0.170 n/a
$227 Letter to Shareholders 26 Feb 2010 10:03AM n/a $0.160 $0.170 n/a
$227 Appendix 4C - quarterly 29 Jan 2010 2:44PM $0.200 $0.160 $0.170 fallen by 20%
$227 BioDiem regains Japanese rights to LAIV 24 Dec 2009 11:16AM $0.210 $0.160 $0.170 fallen by 23.81%
$227 Extension of Co-operative Research Development Agreement 27 Oct 2009 11:59AM $0.210 $0.160 $0.170 fallen by 23.81%
$227 WHO issues a further sublicence of LAIV 27 Oct 2009 11:58AM $0.210 $0.160 $0.170 fallen by 23.81%
$227 Appendix 4C - quarterly 22 Oct 2009 10:36AM $0.200 $0.160 $0.170 fallen by 20%
$227 LAIV Proof of Concept Trial 14 Oct 2009 9:48AM n/a $0.160 $0.170 n/a
$227 WHO Sub-licences BioDiem`s LAIV Technology 2 Sep 2009 11:56AM $0.210 $0.160 $0.170 fallen by 23.81%
$227 Agreement with PATH for Prototype Pandemic Influenza Vaccine 1 Sep 2009 11:02AM $0.160 $0.160 $0.170 fallen by 0%
$227 Completion of Phase I Clinical Trial Recruitment for LAIV 31 Aug 2009 10:38AM n/a $0.160 $0.170 n/a
$227 Preliminary Final Report 19 Aug 2009 4:19PM $0.120 $0.160 $0.170 risen by 33.33%
$227 Appendix 4C - quarterly 31 Jul 2009 3:34PM n/a $0.160 $0.170 n/a
$227 BioDiem supports WHO`s Global Pandemic Influenza Action Plan 25 May 2009 10:43AM $0.130 $0.160 $0.170 risen by 23.08%
$227 Appendix 4C - quarterly 28 Apr 2009 10:23AM $0.150 $0.160 $0.170 risen by 6.67%
$227 Half Year Financial Reports 26 Feb 2009 10:32AM n/a $0.160 $0.170 n/a
$227 Commencement of Phase I clinical trials for LAIV 24 Feb 2009 4:12PM $0.070 $0.160 $0.170 risen by 128.57%
$227 Appendix 4C - quarterly 30 Jan 2009 10:43AM n/a $0.160 $0.170 n/a
$227 Phase II data of H5 vaccine confirms safety, immunogenicity 5 Dec 2008 9:49AM n/a $0.160 $0.170 n/a
$227 BioDiem receives 6th milestone of US$1m for flu vaccine 28 Nov 2008 1:28PM $0.080 $0.160 $0.170 risen by 100%
$227 Appendix 4C - quarterly 31 Oct 2008 1:09PM $0.075 $0.160 $0.170 risen by 113.33%
$227 Extension of Co-operative Research and Development Agreement 20 Oct 2008 9:20AM $0.075 $0.160 $0.170 risen by 113.33%
$227 Preliminary Final Report 29 Aug 2008 3:29PM $0.110 $0.160 $0.170 risen by 45.45%
$227 Appendix 4C - quarterly 24 Jul 2008 9:48AM $0.115 $0.160 $0.170 risen by 39.13%

276 - 300 of 351 results

Page 12 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.